Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

Nathan A. Berger(University School), Csaba Szabó(University of Fribourg), Ted M. Dawson(Johns Hopkins University), Alexander Bürkle(University of Konstanz), Raymond A. Swanson(San Francisco VA Medical Center), Balázs Sümegi(University of Szeged), Flavio Moroni(University of Florence), Valina L. Dawson(Johns Hopkins University), Alberto Chiarugi(Azienda Ospedaliero-Universitaria Careggi), György Haskó(Columbia University), Robert S. B. Clark(Children's Hospital of Pittsburgh), Lucas Liaudet(University Hospital of Lausanne), Valérie C. Besson(Inserm), Salvatore Cuzzocrea(University of Messina), Francisco García Soriano(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), A. Hamid Boulares(Louisiana State University Health Sciences Center New Orleans), Robert P. Strosznajder(Mossakowski Medical Research Institute, Polish Academy of Sciences), Pál Pacher(National Institutes of Health), Peter Radermacher(Universität Ulm), Nicola J. Curtin(Newcastle University), Andrew L. Salzman(BD Biosciences (United States)), Solomon H. Snyder(Johns Hopkins University)
British Journal of Pharmacology
February 18, 2017
Cited by 210


Related Papers